Education
About Us
Working with TipRanks
Follow Us
Pulmatrix (PULM)
:PULM
Top Page
Pulmatrix
(NASDAQ:PULM)
56Neutral
Pulmatrix (PULM) vs. S&P 500 (SPY)
Market Cap
$26.99M
Dividend YieldN/A
Average Volume (3M)35.81K
Price to Earnings (P/E)―
Beta (1Y)-1.25
Revenue Growth47.05%
EPS Growth40.66%
CountryUS
Employees22
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.64
Shares Outstanding3,652,285
10 Day Avg. Volume26,913
30 Day Avg. Volume35,807
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.70
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pulmatrix Business Overview & Revenue Model
Company DescriptionPulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on the development of inhaled therapies to address serious pulmonary diseases. Operating within the pharmaceuticals and biotechnology sectors, the company employs its proprietary iSPERSE technology to design and develop novel inhalation therapies targeting respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and other lung-related conditions.
How the Company Makes MoneyPulmatrix generates revenue primarily through the development and commercialization of its inhaled therapeutic products. The company earns money through strategic partnerships and collaborations with other pharmaceutical companies, which provide funding for research and development, as well as potential milestone and royalty payments upon successful commercialization of its products. Additionally, Pulmatrix may receive revenue from licensing its iSPERSE technology to third parties for their own product development. The company's financial success heavily relies on the successful progression of its drug candidates through clinical trials and eventual market approval.
Pulmatrix Financial Statement Overview
Summary
Pulmatrix shows growth in revenue but struggles with profitability and cash flow management. The company's strong equity position offsets some financial risks, but continuous operational losses and negative cash flows highlight the need for strategic adjustments to improve financial health.Income Statement
Pulmatrix's revenue has increased significantly in the TTM, showing a positive revenue growth trend from the previous annual period. However, profitability remains a concern as the company is operating at a net loss, with negative EBIT and EBITDA margins indicating financial challenges in managing operational costs.35
Negative
Balance Sheet
The company maintains a strong equity position with no debt in the latest period, reflected in a low debt-to-equity ratio and a high equity ratio. However, a declining trend in stockholders' equity over the past years indicates potential sustainability concerns.58
Neutral
Cash Flow
Pulmatrix's cash flow situation is under pressure with negative free cash flow and operating cash flow in the TTM. The lack of positive cash flow generation indicates ongoing challenges in funding operations without external financing.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 4.02M | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | Gross Profit |
| -11.46M | -8.22M | 4.53M | -10.21M | 12.63M | -4.93M | EBIT |
| -21.75M | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | EBITDA |
| -17.02M | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | Net Income Common Stockholders |
| -21.78M | -14.12M | -18.73M | -22.50M | -28.52M | -20.39M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.56M | 19.17M | 35.63M | 53.84M | 31.66M | 23.44M | Total Assets |
| 14.72M | 33.96M | 40.95M | 58.82M | 38.17M | 36.10M | Total Debt |
| 0.00 | 8.76M | 857.00K | 2.29M | 1.74M | 675.00K | Net Debt |
| -2.56M | -10.42M | -34.77M | -51.55M | -29.91M | -22.77M | Total Liabilities |
| 2.88M | 15.96M | 9.84M | 11.37M | 15.03M | 25.08M | Stockholders Equity |
| 11.84M | 18.00M | 31.11M | 47.45M | 23.14M | 11.02M |
| Cash Flow | Free Cash Flow | ||||
| -18.62M | -16.66M | -19.44M | -19.87M | -12.76M | 3.17M | Operating Cash Flow |
| -18.41M | -15.98M | -19.36M | -19.73M | -12.48M | 3.23M | Investing Cash Flow |
| -203.00K | -676.00K | -86.00K | -144.00K | -281.00K | -58.00K | Financing Cash Flow |
| 6.04M | 53.00K | 1.23M | 43.48M | 20.98M | 17.70M |
Pulmatrix Technical Analysis
Positive
8.11
Price Trends
7.28
Positive
5.85
Positive
3.95
Positive
Market Momentum
0.01
Positive
54.52
Neutral
49.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PULM, the sentiment is Positive. The current price of 8.11 is above the 20-day moving average (MA) of 7.96, above the 50-day MA of 7.28, and above the 200-day MA of 3.95, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 49.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PULM.
Pulmatrix Risk Analysis
Pulmatrix disclosed 45 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulmatrix Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.10B | 83.22 | 3.42% | ― | 14.88% | -86.70% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
60 Neutral | $1.34B | ― | -23.01% | ― | 168.06% | 44.66% | |
56 Neutral | $26.99M | ― | -62.70% | ― | 47.05% | 40.66% | |
53 Neutral | $421.09M | ― | 91.25% | ― | -12.26% | 32.86% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
46 Neutral | $249.73M | ― | -33.88% | ― | ― | -22.66% |
* Healthcare Sector Average
Performance Comparison
PULM
Pulmatrix
8.11
6.37
366.09%
INVA
Innoviva
17.41
2.69
18.27%
VRTX
Vertex Pharmaceuticals
495.42
86.65
21.20%
AKBA
Akebia Therapeutics
1.93
0.56
40.88%
ARDX
Ardelyx
5.44
-2.59
-32.25%
AVIR
Atea Pharmaceuticals
3.10
-0.75
-19.48%
Pulmatrix Corporate Events
M&A TransactionsDividendsBusiness Operations and Strategy
Pulmatrix and Cullgen Announce Strategic Merger Agreement
Positive
Nov 13, 2024
Pulmatrix and Cullgen have announced a merger to form a Nasdaq-listed entity focused on targeted protein degradation, with promising clinical trials in cancer and pain management underway. The merger, expected to finalize by March 2025, will see Cullgen shareholders owning the majority stake, while Pulmatrix plans to distribute a cash dividend to its shareholders. This strategic move aims to enhance growth through Cullgen’s innovative drug development platform, with the combined company holding approximately $65 million in funds to support multiple clinical milestones.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.